Fangsheng Pharmaceutical: Silymarin tablets obtain "Drug Registration Certificate"

Fangsheng Pharmaceutical announced that the company's research and development of the drug Silepag tablets has obtained a drug approval number and can now be produced. Silepag tablets were originally developed by Actelion in Switzerland and were first approved for sale in the United States in December 2015 under the brand name UPTRAVI. They are used to treat pulmonary arterial hypertension, to delay disease progression, and to reduce the risk of hospitalization due to pulmonary arterial hypertension.